Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Gongwin Biopharm Holdings Co's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Gongwin Biopharm Holdings Co's Dividend Payout Ratio or its related term are showing as below:
ROCO:6617's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.44 * Ranked among companies with meaningful Dividend Payout Ratio only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Gongwin Biopharm Holdings Co (ROCO:6617) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Gongwin Biopharm Holdings Co Dividend Payout Ratio Related Terms
Gongwin Biopharm Holdings Co Dividend Payout Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gongwin Biopharm Holdings Co Dividend Payout Ratio Chart
ROCO:6617 vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gongwin Biopharm Holdings Co Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Gongwin Biopharm Holdings Co's Dividend Payout Ratio falls into.
Gongwin Biopharm Holdings Co Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Gongwin Biopharm Holdings Co's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gongwin Biopharm Holdings Co (ROCO:6617) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Gongwin Biopharm Holdings Co and its competitors. According to the industry distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 133 companies in the Biotechnology industry.
Is Gongwin Biopharm Holdings Co's Dividend Payout Ratio too high?
Gongwin Biopharm Holdings Co's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 133 companies for Dividend Payout Ratio. This places Gongwin Biopharm Holdings Co in the lower half of its industry. The industry median Dividend Payout Ratio is 0.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.44, based on 133 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Gongwin Biopharm Holdings Co and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gongwin Biopharm Holdings Co's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co (ROCO:6617) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$151.75, compared to a current price of NT$103.00 — trading 32.1% below its estimated fair value. The current Dividend Payout Ratio is 0.00. Gongwin Biopharm Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gongwin Biopharm Holdings Co (ROCO:6617) Overvalued in 2026?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co stock appears to be undervalued.
The current stock price of NT$103.00 is trading 32.1% below its estimated GF Value™ of NT$151.75.
GuruFocus considers Gongwin Biopharm Holdings Co to be Significantly Undervalued.
Key valuation signals for ROCO:6617:
Dividend Payout Ratio: 0.00
GF Value™: NT$151.75 vs. price of NT$103.00 (32.1% below fair value)
No single metric tells the full story. See the ROCO:6617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
70GF Score
Get the complete analysis for ROCO:6617
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6617 has been successfully added to your 
